FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS
Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in…
Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort
NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
Strength Building: How Strength Training Supplements Help You Build Muscle Mass and Keep Growing Stronger – CrazyBulk
New York City, NY, July 28, 2025 (GLOBE NEWSWIRE) -- Build muscle…
FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: U.S. POINTER STUDY SHOWS STRUCTURED LIFESTYLE PROGRAM TARGETING MULTIPLE RISK FACTORS IMPROVES COGNITION IN OLDER ADULTS AT RISK OF COGNITIVE DECLINE
Key Takeaways Two lifestyle interventions in U.S. POINTER improved cognition in older…
Siemens Healthineers Receives Frost & Sullivan’s 2025 North America Company of the Year Award for Excellence in Advanced Visualization Applications
Recognized for delivering diagnostic innovation, workflow efficiency, and enterprise imaging leadership through…
Testosterone Booster for Muscle Gain: Men Opt for OTC Supplement Form Natural Testosterone Replacement Therapy (TRT) Treatment in 2025
New York City, NY, July 27, 2025 (GLOBE NEWSWIRE) -- A recent…
Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025
July 25, 2025 16:15 ET | Source: Portage Biotech Inc. DOVER, Del.,…
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
– Phase 1a clinical data in healthy participants presented for both ABI-5366…
Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis onAugust 5, 2025
SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi”…